Skip to main content
European Commission logo
italiano italiano
CORDIS - Risultati della ricerca dell’UE
CORDIS

CANCER PREVENTION VS CANCER TREATMENT: THE RARE TUMOUR RISK SYNDROMES BATTLE

Descrizione del progetto

Una strategia di sorveglianza per la prevenzione delle sindromi rare di predisposizione al cancro

Le sindromi rare di predisposizione al cancro (RTRS, Rare Tumour Risk Syndrome) sono malattie infrequenti provocate da varianti genetiche ereditarie che comportano un rischio molto elevato di insorgenza tumorale. I pazienti affetti da RTRS non diagnosticate sviluppano cancri particolarmente aggressivi, che portano a morte prematura. Qualora si sorveglino i pazienti asintomatici affetti da RTRS, applicando interventi di tipo precoce, è possibile prevenire i tumori sviluppati a partire da tali sindromi. Tra gli obiettivi del progetto PREVENTABLE, finanziato dall’UE, figurano la fusione delle conoscenze cliniche sui percorsi di assistenza per le RTRS con i dati clinici e le esperienze di pazienti reali affetti da RTRS, nonché con modelli economici sanitari e un approccio basato sulle scienze sociali. Il progetto metterà in evidenza i costi e i benefici associati agli interventi per la riduzione dei rischi nelle RTRS, fornendo quindi linee guida per una migliore comunicazione tra le équipe mediche e i pazienti interessati.

Obiettivo

Rare tumour risk syndromes (RTRS) are rare diseases, affecting 5 per 10.000 people or less and caused by heritable genetic variants. In RTRS, the lifetime risk to develop various cancers can be as high as 100%, and patients have a 50% chance of transmitting the disease to their offspring. When undiagnosed or not surveilled, many asymptomatic RTRS patients develop particularly aggressive cancers, leading to premature death, severely impacting theirs and their families’ health and wellbeing. Cancers in RTRS can be prevented and survival rates maximized if asymptomatic RTRS patients are intensively surveilled for RTRS-prone organs, cancer-prone organs are surgically removed prior to disease development, or very small cancerous or pre-cancerous lesions are removed or treated. RTRS are therefore a unique and tangible context for cancer prevention, early diagnosis and treatment with curative intent. However, risk-reduction strategies are not always prioritized in genetically diagnosed and asymptomatic RTRS patients, and most healthcare systems keep on opting for treatment of clinically expressed cancer. This occurs despite the knowledge that hospitalization has the highest weight on advanced cancer healthcare spending. It is therefore urgent to demonstrate the cost-benefit of the application of preventive measures in RTRS syndromes.
The ambition of the PREVENTABLE project is to merge specialized clinical knowledge on RTRS pathways of care, real-life clinical data from RTRS patients and experiences from professionals and patients, with health economic models and social sciences approaches to estimate the cost-benefit of risk-reduction interventions in RTRS and delineate guidelines for its communication among and within clinical teams and RTRS patients. PREVENTABLE project results will be delivered to a diversity of stakeholders, including policy-makers, in order to promote the implementation of cost-effective RTRS patient-centered care in Europe.

Coordinatore

I3S - INSTITUTO DE INVESTIGACAO E INOVACAO EM SAUDE DA UNIVERSIDADE DO PORTO
Contribution nette de l'UE
€ 1 660 005,00
Indirizzo
RUA ALFREDO ALLEN 208
4200-135 Porto
Portogallo

Mostra sulla mappa

Regione
Continente Norte Área Metropolitana do Porto
Tipo di attività
Research Organisations
Collegamenti
Costo totale
€ 2 065 602,25

Partecipanti (13)

Partner (1)